FDA Warns Of Mortality Risks From Wyeth Antibiotic
“Alternatives to Tygacil should be considered in patients with severe infections,” the agency stated in its recommendation.
The FDA also sent out “Dear Healthcare Professional” letters reminding doctors of the risk Tygacil poses as compared with other treatments for severe infections. The letters and labels carefully point out, however, that the greatest mortality...
To view the full article, register now.